{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:46:12Z","timestamp":1792431972362,"version":"4.5.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:p>The PROMISE diagnostic algorithm, which uses p53, mismatch repair (MMR) protein immunohistochemistry, and DNA polymerase \u03b5 (<jats:italic toggle=\"yes\">POLE<\/jats:italic>) exonuclease domain mutation testing, is a reliable surrogate of the molecular group in endometrial carcinoma. Its prognostic value has been validated in endometrial carcinoma and ovarian endometrioid carcinoma. Moreover, a similar prognostic grouping has been recently documented in endometrial clear cell carcinoma. Thus, we aimed to explore the role of these markers in ovarian clear cell carcinoma, another endometriosis-associated malignancy. A total of 90 cases were identified and confirmed after secondary review. Immunohistochemistry for p53, MLH1, MSH2, MSH6, and PMS2 was performed in formalin-fixed, paraffin-embedded tissue. <jats:italic toggle=\"yes\">POLE<\/jats:italic> mutational analysis was performed in 47 cases. Results were correlated with clinicopathologic variables including disease-free survival (DFS), overall survival, and disease-specific survival (DSS). Endometriosis was found in 67 (74%) cases. Six (7%) tumors were p53 abnormal, 82 (91%) were p53 normal, and 2 (2%) tumors had MMR deficiency (1 MSH6 loss and 1 MSH2\/6 loss; both were p53 normal). Several <jats:italic toggle=\"yes\">POLE<\/jats:italic> variants of unknown significance were detected, but no pathogenic mutations. The mean follow-up period was 43 months (median: 34, range: 1 to 189). Abnormal p53 status was associated with advanced Federation of Gynecology and Obstetrics stage, lymph node metastases, DFS and DSS (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.05, Fisher exact test). In univariate analysis, abnormal p53 and positive lymph node status had worse DFS, whereas bilaterality, surface involvement, and advanced stage were associated with worse DFS, overall survival and DSS (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.05, Cox regression). On multivariate analysis, only stage retained statistical association with survival. Using a molecular-based approach designed for endometrial carcinoma, most ovarian clear cell carcinomas fall into the copy-number-low molecular subgroup. However, a small but important subset has an abnormal p53 expression (copy-number-high group). This subset is associated with adverse features including extrapelvic disease, nodal metastases, and recurrence similar to endometrial and ovarian endometrioid cancer. Thus, testing for this marker has potential prognostic significance. The role of other markers in the PROMISE algorithm remains to be elucidated, as we found a low frequency of MMR abnormalities and no pathogenic <jats:italic toggle=\"yes\">POLE<\/jats:italic> mutations in our series.<\/jats:p>","DOI":"10.1097\/pas.0000000000001328","type":"journal-article","created":{"date-parts":[[2019,7,21]],"date-time":"2019-07-21T21:38:50Z","timestamp":1563745130000},"page":"1591-1599","source":"Crossref","is-referenced-by-count":52,"title":["p53, Mismatch Repair Protein, and POLE Abnormalities in Ovarian Clear Cell Carcinoma"],"prefix":"10.1097","volume":"43","author":[{"given":"Carlos","family":"Parra-Herran","sequence":"first","affiliation":[{"name":"Laboratory Medicine and Molecular Diagnostics"},{"name":"Laboratory Medicine and Pathobiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Bassiouny","sequence":"additional","affiliation":[{"name":"Laboratory Medicine and Molecular Diagnostics"},{"name":"Department of Pathology, Mansoura University, Mansoura, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Lerner-Ellis","sequence":"additional","affiliation":[{"name":"Laboratory Medicine and Pathobiology"},{"name":"Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Sinai Health System"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Olkhov-Mitsel","sequence":"additional","affiliation":[{"name":"Laboratory Medicine and Molecular Diagnostics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Ismiil","sequence":"additional","affiliation":[{"name":"Laboratory Medicine and Molecular Diagnostics"},{"name":"Laboratory Medicine and Pathobiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liat","family":"Hogen","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynaecology, University of Toronto"},{"name":"Department of Gynecologic Oncology, University Health Network, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Vicus","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology, Sunnybrook Health Sciences Centre"},{"name":"Obstetrics and Gynaecology, University of Toronto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Nofech-Mozes","sequence":"additional","affiliation":[{"name":"Laboratory Medicine and Molecular Diagnostics"},{"name":"Laboratory Medicine and Pathobiology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br J Cancer"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1038\/modpathol.2017.81","article-title":"Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups","volume":"30","author":"Parra-Herran","year":"2017","journal-title":"Mod Pathol"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ajpath.2015.11.011","article-title":"The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded","volume":"186","author":"Kurman","year":"2016","journal-title":"Am J Pathol"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/ng.3849","article-title":"Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes","volume":"49","author":"Wang","year":"2017","journal-title":"Nat Genet"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/path.4934","article-title":"Clear cell and endometrioid carcinomas: are their differences attributable to distinct cells of origin?","volume":"243","author":"Cochrane","year":"2017","journal-title":"J Pathol"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/path.4947","article-title":"The genetic landscape of endometrial clear cell carcinomas","volume":"243","author":"DeLair","year":"2017","journal-title":"J Pathol"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1136\/jmedgenet-2014-102933","article-title":"Canadian Open Genetics Repository (COGR): a unified clinical genomics database as a community resource for standardising and sharing genetic interpretations","volume":"52","author":"Lerner-Ellis","year":"2015","journal-title":"J Med Genet"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/PGP.0b013e3181c042b6","article-title":"Differences in tumor type in low-stage versus high-stage ovarian carcinomas","volume":"29","author":"K\u00f6bel","year":"2010","journal-title":"Int J Gynecol Pathol"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1371\/journal.pmed.0050232","article-title":"Ovarian carcinoma subtypes are different diseases: implications for biomarker studies","volume":"5","author":"K\u00f6bel","year":"2008","journal-title":"PLoS Med"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.humpath.2008.01.003","article-title":"Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma","volume":"39","author":"Gilks","year":"2008","journal-title":"Hum Pathol"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1097\/PAS.0b013e3181e1a3bb","article-title":"Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study","volume":"34","author":"K\u00f6bel","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/his.12349","article-title":"Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry","volume":"64","author":"K\u00f6bel","year":"2014","journal-title":"Histopathology"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/modpathol.2010.215","article-title":"Calculator for ovarian carcinoma subtype prediction","volume":"24","author":"Kalloger","year":"2011","journal-title":"Mod Pathol"},{"key":"R17-20230922","first-page":"704","article-title":"Accelerating type-specific ovarian carcinoma research: calculator for ovarian subtype prediction (COSP) is a reliable high-throughput tool for case review","volume":"63","author":"Kommoss","year":"2013","journal-title":"Histopathology"},{"key":"R18-20230922","first-page":"1707","article-title":"Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage","volume":"58","author":"Jiang","year":"1998","journal-title":"Cancer Res"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/PAS.0b013e3181ff400e","article-title":"Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases","volume":"35","author":"DeLair","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/PAS.0b013e3181788546","article-title":"A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary","volume":"33","author":"K\u00f6bel","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/PGP.0b013e3182518557","article-title":"Clinicopathologic and immunohistochemical features of ovarian clear cell carcinomas in comparison with type I and type II tumors","volume":"31","author":"Zannoni","year":"2012","journal-title":"Int J Gynecol Pathol"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/PAS.0000000000001209","article-title":"Targeted molecular and immunohistochemical analyses of endometrial clear cell carcinoma show that POLE mutations and DNA mismatch repair protein deficiencies are uncommon","volume":"43","author":"Baniak","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"R23-20230922","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/PGP.0b013e31824fe2aa","article-title":"Prevalence of loss of expression of DNA mismatch repair proteins in primary epithelial ovarian tumors","volume":"31","author":"Lu","year":"2012","journal-title":"Int J Gynecol Pathol"},{"key":"R24-20230922","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ygyno.2014.07.100","article-title":"Lynch Syndrome in patients with clear cell and endometrioid cancers of the ovary","volume":"135","author":"Vierkoetter","year":"2014","journal-title":"Gynecol Oncol"},{"key":"R25-20230922","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/PAP.0b013e3182a92cf8","article-title":"Identifying Lynch syndrome in patients with ovarian carcinoma: the significance of tumor subtype","volume":"20","author":"Chui","year":"2013","journal-title":"Adv Anat Pathol"},{"key":"R26-20230922","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.humpath.2003.12.009","article-title":"Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma","volume":"35","author":"Cai","year":"2004","journal-title":"Hum Pathol"},{"key":"R27-20230922","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ygyno.2005.10.029","article-title":"The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer","volume":"101","author":"Malander","year":"2006","journal-title":"Gynecol Oncol"},{"key":"R28-20230922","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1525-1438.2007.00875.x","article-title":"Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40","volume":"17","author":"Domanska","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"R29-20230922","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/modpathol.3800672","article-title":"Immunohistochemical staining of hMLH1 and hMSH2 reflects microsatellite instability status in ovarian carcinoma","volume":"19","author":"Rosen","year":"2006","journal-title":"Mod Pathol"},{"key":"R30-20230922","first-page":"502","article-title":"Loss of DNA mismatch repair protein hMSH6 in ovarian cancer is histotype-specific","volume":"1","author":"Zhai","year":"2008","journal-title":"Int J Clin Exp Pathol"},{"key":"R31-20230922","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/PAS.0b013e31816380c4","article-title":"Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger","volume":"32","author":"Jensen","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"R32-20230922","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/PAS.0000000000000298","article-title":"The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy","volume":"38","author":"Chui","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R33-20230922","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ygyno.2015.12.031","article-title":"Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas","volume":"141","author":"Wong","year":"2016","journal-title":"Gynecol Oncol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001328","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T22:51:35Z","timestamp":1695423095000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001328"}},"subtitle":["An Outcome-based Clinicopathologic Analysis"],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001328","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}